NYMC Faculty Publications
Severe Mpox Among People With Advanced Human Immunodeficiency Virus Receiving Prolonged Tecovirimat in New York City
Author Type(s)
Faculty
DOI
10.1093/ofid/ofae294
Journal Title
Open Forum Infectious Diseases
First Page
294
Last Page
294
Document Type
Article
Publication Date
6-2024
Department
Medicine
Keywords
mortality; HIV/AIDS; immunocompromise; mpox treatment; tecovirimat
Disciplines
Medicine and Health Sciences
Abstract
Severe mpox has been observed in people with advanced human immunodeficiency virus (HIV). We describe clinical outcomes of 13 patients with advanced HIV (CD4 < 200 cells/μL), severe mpox, and multiorgan involvement. Despite extended tecovirimat courses and additional agents, including vaccinia immune globulin, cidofovir, and brincidofovir, this group experienced prolonged hospitalizations and high mortality.
Recommended Citation
Garcia, E. A., Foote, M. M., McPherson, T. D., Lash, M. K., Bosompem, A. N., Bouscaren, A., Chan, J., DiLorenzo, M. A., Feihel, D., Fowler, R. C., Gandhi, V., Jenny-Avital, E. R., Kopping, E. J., Mazo, D., McLean, J., Mgbako, O., Sayegh, M. N., Shaw, R. N., Su, M., Meissner, J., Wang, J. C., Wen, W., Winters, J. C., Zeana, C. B., Zucker, J., & Wong, M. (2024). Severe Mpox Among People With Advanced Human Immunodeficiency Virus Receiving Prolonged Tecovirimat in New York City. Open Forum Infectious Diseases, 11 (6), 294-294. https://doi.org/10.1093/ofid/ofae294
